Sign up
Pharma Capital

Synairgen planning winter trial as it develops inhaled interferon beta drug for COPD

Richard Marsden, chief executive of Synairgen plc (LON:SNG) tells Proactive they're to  develop their inhaled interferon beta drug SNG001 as a potential treatment for chronic obstructive pulmonary disease (COPD) after a review of data indicated it can boost the lungs’ antiviral capabilities.

A short trial is being planned this winter to test the COPD potential.

Marsden also discusses their upcoming LOXL2 trial.

PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.

Results from the Phase I trial are scheduled for the middle of 2018, after which the aim is to find a partner to license the drug due to size of the potential market and number of indications it could address.

 

View full SNG profile

Synairgen plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.